EVOK - Evoke Pharma Inc

11
0.040   0.364%

Share volume: 47,105
Last Updated: 12-16-2025
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$10.96
0.04
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
38%
Profitability 50%
Dept financing 12%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0.64%
6 Months
111.54%
1 Year
183.51%
2 Year
1,482.73%
Key data
Stock price
$11.00
P/E Ratio 
0.00
DAY RANGE
$10.98 - $11.00
EPS 
-$2.21
52 WEEK RANGE
$1.94 - $11.00
52 WEEK CHANGE
$192.86
MARKET CAP 
7.746 M
YIELD 
N/A
SHARES OUTSTANDING 
1.722 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
1.07
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: David A. Gonyer
Region: US
Website: evokepharma.com
Employees: 4
IPO year: 2013
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Evoke Pharma, Inc. is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers.

Recent news